<DOC>
	<DOCNO>NCT02368691</DOCNO>
	<brief_summary>The purpose study determine GTx-024 effective safe treatment patient advance , androgen receptor positive triple negative breast cancer ( AR+ TNBC ) .</brief_summary>
	<brief_title>Efficacy Safety GTx-024 Patients With Androgen Receptor-Positive Triple Negative Breast Cancer ( AR+ TNBC )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Able willing give voluntary , write sign , inform consent Women ≥ 18 year age Women TNBC receive least one two prior chemotherapy regimens TNBC Confirmation AR+ ( define ≥ 10 % nuclear AR stain immunohistochemistry [ IHC ] ) TNBC either primary metastatic lesion , assess screening period local laboratory medical history TNBC confirm medical history : human epidermal growth factor receptor 2 [ HER2 ] negative ( confirm IHC 0 , 1+ regardless fluorescence situ hybridization [ FISH ] ratio ; IHC 2+ FISH ratio low 2.0 HER2 gene copy le 6.0 ; FISH ratio 0 , indicate gene deletion , positive negative situ hybridization [ ISH ] control present ) ; estrogen receptor ( ER ) negative ( confirm ER expression less equal 1 % positive tumor nucleus ) ; progesterone receptor negative ( confirm progesterone receptor expression less equal 1 % positive tumor nucleus ) Availability paraffin embed formalin fixed tumor tissue ; OR , minimum 10 20 slide archive tumor tissue central laboratory confirmation AR status molecular subtyping . Metastatic tumor tissue prefer possible Subjects must either measurable disease boneonly nonmeasurable disease , evaluable accord RECIST 1.1 Subjects bone metastasis treat intravenous bisphosphonates subcutaneous denosumab ( investigator prefer standard care ) prior trial , unless contraindication subject intolerance therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 time screen enrollment Negative pregnancy test woman childbearing potential ( premenopausal less 12 month amenorrhea postmenopause , undergone surgical sterilization ) , 7 day first dose study treatment For woman childbearing potential sexually active , agreement use highly effective , nonhormonal form contraception least 6 month completion study treatment ; OR , fertile male partner willing able use effective nonhormonal contraception ( barrier method contraception conjunction spermicidal jelly , surgical sterilization ) least 6 month completion study treatment Adequate organ function show : Absolute neutrophil count ≥ 1,000 cells/mm3 Platelet count ≥ 100,000 cells/mm3 Hemoglobin ≥ 9 g/dL Serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 Upper Limit Normal range ( ULN ) ( ≤ 5 hepatic metastasis present ) Total serum bilirubin ≤ 2.0 × ULN ( unless subject document Gilbert Syndrome ) Alkaline phosphatase level ≤ 2.5 × ULN ( ≤ 5 × ULN subject liver metastasis ) Serum creatinine &lt; 2.0 mg/dL 177 μmol/L International normalize ratio ( INR ) , activate partial thromboplastin time ( aPTT ) , partial thromboplastin time ( PTT ) &lt; 1.5 × ULN ( unless anticoagulant treatment screen ) Able swallow capsule Any toxicity prior chemotherapy resolve Grade 1 ( NCICTCAE , Version 4.0 ) Life expectancy &lt; 4 month ; Subjects radiographic evidence central nervous system ( CNS ) metastases assessed computerized tomography ( CT ) magnetic resonance imaging ( MRI ) well control ( symptomatic require control continuous corticosteroid therapy [ e.g. , dexamethasone ] ) . Note : Subjects CNS metastasis permit participate study CNS metastases medically well control prior screening ( assessed Investigator ) receive local therapy ( irradiation , surgery , etc . ) Radiotherapy within 14 day prior first dose study treatment Have , judgment Investigator , clinically significant concurrent illness psychological , familial , sociological , geographical , concomitant condition would permit adequate followup compliance study protocol Positive hepatitis B virus ( HBV ) and/or hepatitis C virus ( HCV ) infection screen Positive human immunodeficiency virus ( HIV ) infection screen Prior treatment antiandrogens , include limited , enzalutamide bicalutamide Major surgery within 28 day first dose study treatment Be currently take previously take testosterone , methyltestosterone , oxandrolone ( Oxandrin® ) , oxymetholone , danazol , fluoxymesterone ( Halotestin® ) , testosteronelike agent ( dehydroepiandrosterone , androstenedione , androgenic compound , include herbal ) , antiandrogens Treatment follow hormone replacement therapy , unless discontinue least 14 day prior first dose study treatment : Estrogens Megesterol acetate Treatment investigational agent within 28 day first dose study treatment Another active cancer ( exclude adequately treat basal cell carcinoma cervical intraepithelial neoplasia [ CIN ] /cervical carcinoma situ melanoma situ ) . Prior history cancer allow long active disease within prior 5 year Subject concomitant medical condition precludes adequate study treatment compliance assessment , increase subject risk , opinion Investigator , limit : Myocardial infarction arterial thromboembolic event within 6 month prior baseline severe unstable angina , New York Heart Association ( NYHA ) Class III IV disease , QTcB ( correct accord Bazett 's formula ) interval &gt; 470 msec ; serious uncontrolled cardiac arrhythmia grade II high accord NYHA ; uncontrolled hypertension ( systolic &gt; 150 and/or diastolic &gt; 100 mm Hg ) Acute chronic active infectious disorder nonmalignant medical illness uncontrolled whose control may jeopardize complication study therapy Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome ) Current treatment intravenous bisphosphonate denosumab elevate serum calcium correct albumin ionized calcium level outside institutional normal limit screen History noncompliance medical regimen Subjects unwilling unable comply protocol procedure assess Investigator Concurrent participation another therapeutic clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>